Intravenous immunoglobulin for pyoderma gangrenosum

nazole against dermatophytes causing tinea pedis and tinea cruris ⁄corporis such as T. rubrum, T. mentagrophytes and M. canis as demonstrated in vitro and in animal models is confirmed by these studies in patients. Although we realize that the number of patients in this trial is limited, there is a tendency for a better response towards T. rubrum than towards M. canis. Many studies have been performed with different oral antifungals in tinea infections, most of them with treatment schedules ranging from 2 to 6 weeks. Itraconazole trials using shorter treatment schedules of 1 or 2 weeks and doses ranging from 100 to 400 mg daily have been published. Pramiconazole, applied in treatment schedules of short duration, most probably owes its efficacy to its favourable kinetics, i.e. prolonged half-life in blood and possibly lower protein binding than its predecessor molecule itraconazole. In conclusion, these phase IIa trials suggest that pramiconazole possesses properties that warrant further clinical studies for short-term treatment in patients with tinea pedis and tinea cruris ⁄corporis.

[1]  G. Anhalt,et al.  Treatment of pyoderma gangrenosum with intravenous immunoglobulin , 2007, The British journal of dermatology.

[2]  F. Lawlor,et al.  Intravenous immunoglobulin is effective as a sole immunomodulatory agent in pyoderma gangrenosum unresponsive to systemic corticosteroids , 2007, Clinical and experimental dermatology.

[3]  G. Piérard,et al.  The activity of R126638, a new triazole antifungal, as assessed by corneofungimetry , 2005 .

[4]  Aditya K. Gupta,et al.  Dermatophytosis: the management of fungal infections. , 2005, Skinmed.

[5]  T. Gambichler,et al.  Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. , 2004, Journal of the American Academy of Dermatology.

[6]  L. Meerpoel,et al.  The Novel Azole R126638 Is a Selective Inhibitor of Ergosterol Synthesis in Candida albicans, Trichophyton spp., and Microsporum canis , 2004, Antimicrobial Agents and Chemotherapy.

[7]  J. Heeres,et al.  In Vitro and In Vivo Activities of the Novel Azole Antifungal Agent R126638 , 2004, Antimicrobial Agents and Chemotherapy.

[8]  R. Parslew,et al.  Superficial granulomatous pyoderma treated with intravenous immunoglobulin. , 2003, Journal of the American Academy of Dermatology.

[9]  A. Evans,et al.  Response of livedoid vasculitis to intravenous immunoglobulin , 2002, The British journal of dermatology.

[10]  S. Chimenti,et al.  The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum , 2001, The Journal of dermatological treatment.

[11]  H. Williams,et al.  A systematic review of oral treatments for fungal infections of the skin of the feet. , 2001, The Journal of dermatological treatment.

[12]  B. Wanscher,et al.  Efficacy and Safety of Short-Term Itraconazole in Tinea pedis: A Double-Blind, Randomized, Placebo-Controlled Trial , 1998, Dermatology.

[13]  S. Whittaker,et al.  Dermatological uses of high-dose intravenous immunoglobulin. , 1998, Archives of dermatology.

[14]  N. Shear,et al.  Efficacy of human intravenous immune globulin in pyoderma gangrenosum. , 1995, Journal of the American Academy of Dermatology.

[15]  D. Massart,et al.  Two‐week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double‐blind, multicentre study , 1994, The British journal of dermatology.

[16]  G. Cauwenbergh,et al.  Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review. , 1990, British journal of clinical practice. Supplement.